Minimizing intestinal dysfunction

Patent metadata

Field	Value
Publication number	US-2016367642-A1
Application number	US-201615044356-A
Country	US
Kind code	A1
Filing date	Feb 16, 2016
Priority date	Oct 2, 2010
Publication date	Dec 22, 2016
Grant date	—

Abstract

Techniques are disclosed for treating or reducing symptoms associated with abdominal dysfunction or ileus following surgery or other abdominal episode by treating the area with a combination of one or more protease, antibacterial compound, and inflammatory lipid mediator.

First claim

What is claimed is:

1 . A method for treating ilieus, the method comprising:
administering to an individual a therapeutic dose of one or more of the following:
a protease;
an antibacterial compound; and
an inflammatory lipid mediator.

2 . The method of claim 1 , wherein the protease inhibitor is effective for inhibiting the function of one or more of the following: serine protease, plasma protease, MMP, amylase and lipase.

3 . The method of claim 2 , wherein the protease inhibitor includes cyclokapron.

4 . The method of claim 3 , wherein the dose of cyclokapron is 10 to 50 mg/100 ml.

5 . The method of claim 1 , wherein the antibacterial compound is effective against gram-positive and gram-negative bacteria.

6 . The method of claim 5 , wherein the antibacterial compound includes one or more of ciprofloxacin, metronidazole, imipenem and cilastatin, ticarcillin and clavulanate, cefuroxime, doxycycline.

7 . The method of claim 1 , wherein the inflammatory lipid mediator includes albumin.

8 . The method of claim 7 , wherein the dose of inflammatory lipid mediator is 10 to 50 mg/100 ml.

9 . The method of claim 1 , wherein the administering step is prophylactically into the abdominal cavity.

10 . A method for treating abdominal dysfunction, the method comprising:
administering to an individual a therapeutic dose of one or more of the following:
a protease;
an antibacterial compound; and
an inflammatory lipid mediator.

11 . The method of claim 10 , wherein the protease inhibitor is effective for inhibiting the function of one or more of the following: serine protease, plasma protease, MMP, amylase and lipase.

12 . The method of claim 11 , wherein the protease inhibitor includes cyclokapron.

13 . The method of claim 12 , wherein the dose of cyclokapron is 10 to 50 mg/100 ml.

14 . The method of claim 10 , wherein the antibacterial compound is effective against gram-positive and gram-negative bacteria.

15 . The method of claim 14 , wherein the antibacterial compound includes one or more of ciprofloxacin, metronidazole, imipenem and cilastatin, ticarcillin and clavulanate, cefuroxime, doxycycline.

16 . The method of claim 10 , wherein the inflammatory lipid mediator includes albumin.

17 . The method of claim 16 , wherein the dose of inflammatory lipid mediator is 10 to 50 mg/100 ml.

18 . The method of claim 10 , wherein the administering step is prophylactically into the abdominal cavity.

Assignees

• Univ California

Inventors

• Delano Frank A
• Schmid-Schoenbein Geert W
• Saltzman Darin

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/497

  containing further heterocyclic rings · CPC title

• A61K31/195 Primary

  having an amino group · CPC title

• A61K31/415

  1,2-Diazoles · CPC title